Experience Fenwick Represents Royalty Pharma in its Purchase of up to $1.5B in Royalties from PTC Therapeutics October 20, 2023
Experience Fenwick Represents Royalty Pharma in Funding Agreements with Ascendis Pharma Totaling up to $150M September 5, 2023
Experience Fenwick Represents Royalty Pharma in Acquisition of Synthetic Royalty Interest in Adstiladrin® from Ferring Pharmaceuticals Totaling up to $500M August 24, 2023
Experience Fenwick Represents Playground Global in IP Due Diligence of Amber Bio's $26M Seed Financing August 3, 2023
Experience Fenwick Represents Royalty Pharma in Acquisition of Royalty Interest in SPINRAZA and pelacarsen from Ionis in Deal Totaling Up to $1.1B January 9, 2023
Experience Fenwick Represents Marshall Wace in IP Due Diligence of Elektrofi's $40M Series B Financing June 13, 2022